Melanocortin receptor-specific pyrrolidine compounds having the structure:
1
and stereoisomer and pharmaceutically acceptable salts thereof, where R
1
, R
2
, and R
3
are as described in the specification, preferably where R
3
is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R
3
optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
具有以下结构的
黑色素皮质素受体特异性
吡咯烷化合物:
1
及其立体异构体和药学上可接受的盐类,其中 R
1
, R
2
和 R
3
如说明书所述,其中 R
3
是具有至少一个取代或未取代的苯基或
萘基芳香环的 D-
氨基酸,其中 R
3
可选地进一步包括一个胺封端基团或一至三个额外的
氨基酸残基,可选地带有一个胺封端基团,这些化合物是一种或多种
黑色素皮质素受体的激动剂、拮抗剂或混合激动剂和拮抗剂,在治疗
黑色素皮质素受体相关疾病和病症方面具有实用性。此外,还公开了结构(I)化合物的合成方法、含有结构(I)化合物的药物组合物及其使用方法。